Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Purpose - The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies. - Pati...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 1998
|
| In: |
Journal of clinical oncology
Year: 1998, Jahrgang: 16, Heft: 8, Pages: 2825-2833 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.1998.16.8.2825 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.1998.16.8.2825 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2825 
|
| Verfasserangaben: | Peter McLaughlin, Antonio J. Grillo-López, Brian K. Link, Ronald Levy, Myron S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence-Bruckler, Christina A. White, Fernando Cabanillas, Vinay Jain, Anthony Dd Ho, John Lister, Ken Wey, David Shen, and Brian K. Dallaire |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1939891868 | ||
| 003 | DE-627 | ||
| 005 | 20251103103921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251103s1998 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.1998.16.8.2825 |2 doi | |
| 035 | |a (DE-627)1939891868 | ||
| 035 | |a (DE-599)KXP1939891868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a McLaughlin, Peter |e VerfasserIn |0 (DE-588)1380587565 |0 (DE-627)1939893615 |4 aut | |
| 245 | 1 | 0 | |a Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma |b half of patients respond to a four-dose treatment program. |c Peter McLaughlin, Antonio J. Grillo-López, Brian K. Link, Ronald Levy, Myron S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence-Bruckler, Christina A. White, Fernando Cabanillas, Vinay Jain, Anthony Dd Ho, John Lister, Ken Wey, David Shen, and Brian K. Dallaire |
| 264 | 1 | |c August 1998 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.11.2025 | ||
| 520 | |a Purpose - The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies. - Patients and Methods - This was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8. Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 intravenously weekly for four doses. - Results - From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13.0 months. Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden. The majority of adverse events occurred during the first infusion and were grade 1 or 2; fever and chills were the most common events. Only 12% of patients had grade 3 and 3% grade 4 toxicities. A human antichimeric antibody was detected in only one patient. - Conclusion - The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy. Toxicity was mild. Attention needs to be paid to the rate of antibody infusion, with titration according to toxicity. Further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy. | ||
| 700 | 1 | |a Grillo-López, A. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Link, B. K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levy, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Czuczman, M. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Williams, M. E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heyman, M. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bence-Bruckler, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a White, C. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cabanillas, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jain, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Lister, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wey, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shen, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dallaire, B. K. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 16(1998), 8, Seite 2825-2833 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program. |
| 773 | 1 | 8 | |g volume:16 |g year:1998 |g number:8 |g pages:2825-2833 |g extent:9 |a Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program. |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.1998.16.8.2825 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2825 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251103 | ||
| 993 | |a Article | ||
| 994 | |a 1998 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 999 | |a KXP-PPN1939891868 |e 479560018X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1200/JCO.1998.16.8.2825"],"eki":["1939891868"]},"origin":[{"dateIssuedDisp":"August 1998","dateIssuedKey":"1998"}],"name":{"displayForm":["Peter McLaughlin, Antonio J. Grillo-López, Brian K. Link, Ronald Levy, Myron S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence-Bruckler, Christina A. White, Fernando Cabanillas, Vinay Jain, Anthony Dd Ho, John Lister, Ken Wey, David Shen, and Brian K. Dallaire"]},"relHost":[{"recId":"313116962","corporate":[{"role":"isb","display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"disp":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program.Journal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"part":{"pages":"2825-2833","issue":"8","year":"1998","extent":"9","text":"16(1998), 8, Seite 2825-2833","volume":"16"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"pubHistory":["1.1983 -"],"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}]}],"physDesc":[{"extent":"9 S."}],"title":[{"subtitle":"half of patients respond to a four-dose treatment program.","title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma","title_sort":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma"}],"person":[{"given":"Peter","family":"McLaughlin","role":"aut","display":"McLaughlin, Peter","roleDisplay":"VerfasserIn"},{"family":"Grillo-López","given":"A. J.","display":"Grillo-López, A. J.","roleDisplay":"VerfasserIn","role":"aut"},{"given":"B. K.","family":"Link","role":"aut","display":"Link, B. K.","roleDisplay":"VerfasserIn"},{"family":"Levy","given":"R.","roleDisplay":"VerfasserIn","display":"Levy, R.","role":"aut"},{"display":"Czuczman, M. S.","roleDisplay":"VerfasserIn","role":"aut","family":"Czuczman","given":"M. S."},{"given":"M. E.","family":"Williams","role":"aut","roleDisplay":"VerfasserIn","display":"Williams, M. E."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Heyman, M. R.","given":"M. R.","family":"Heyman"},{"roleDisplay":"VerfasserIn","display":"Bence-Bruckler, I.","role":"aut","family":"Bence-Bruckler","given":"I."},{"role":"aut","roleDisplay":"VerfasserIn","display":"White, C. A.","given":"C. A.","family":"White"},{"roleDisplay":"VerfasserIn","display":"Cabanillas, F.","role":"aut","family":"Cabanillas","given":"F."},{"given":"V.","family":"Jain","role":"aut","display":"Jain, V.","roleDisplay":"VerfasserIn"},{"given":"Anthony Dick","family":"Ho","role":"aut","roleDisplay":"VerfasserIn","display":"Ho, Anthony Dick"},{"given":"J.","family":"Lister","role":"aut","display":"Lister, J.","roleDisplay":"VerfasserIn"},{"given":"K.","family":"Wey","role":"aut","roleDisplay":"VerfasserIn","display":"Wey, K."},{"display":"Shen, D.","roleDisplay":"VerfasserIn","role":"aut","family":"Shen","given":"D."},{"family":"Dallaire","given":"B. K.","display":"Dallaire, B. K.","roleDisplay":"VerfasserIn","role":"aut"}],"language":["eng"],"recId":"1939891868","note":["Gesehen am 03.11.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a MCLAUGHLINRITUXIMABC1998 | ||